|Systematic (IUPAC) name|
Trametinib had good results for metastatic melanoma carrying the BRAF V600E mutation in a phase III clinical trial. In this mutation, the amino acid valine (V) at position 600 within the BRAF gene has become replaced by glutamic acid (E) making the mutant BRAF gene constituitively active.
In May 2013, trametinib was approved as a single-agent by the Food and Drug Administration for the treatment of patients with V600E mutated metastatic melanoma. Clinical trial data demonstrated that progression on single-agent trametinib occurs within 6 to 7 months. To overcome this, trametinib was combined with the BRAF inhibitor dabrafenib. As a result of this research, on January 8, 2014, the FDA approved the combination of dabrafenib and trametinib for the treatment of patients with BRAF V600E/K-mutant metastatic melanoma.
- Trametinib, NCI Drug Dictionary
- METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).
- "GSK melanoma drugs add to tally of U.S. drug approvals". Reuters. May 30, 2013.
- "Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations" 367 (18). New England Journal of Medicine. November 1, 2012. pp. 1694–703. PMC 3549295. PMID 23020132. doi:10.1056/NEJMoa1210093.
- "Dabrafenib/Trametinib Combination Approved for Advanced Melanoma". OncLive. January 9, 2014.
Lua error in package.lua at line 80: module 'Module:Buffer' not found.